Navigation Links
Drug developed by Hebrew U. and others holds promise for treatment of wounds
Date:2/7/2011

Jerusalem, February 7, 2011 -- A low cost, nanometer-sized drug to treat chronic wounds, such as diabetic foot ulcers or burns, has been developed by a group of scientists from the Hebrew University of Jerusalem, Harvard Medical School and others in the U.S. and Japan.

Diabetes is a rapidly growing medical problem affecting close to 3 percent of the world's population. Poor blood circulation arising from diabetes often results in skin wounds which do not heal, causing pain, infection and at times amputation of limbs.

Several proteins, called growth factors, have been found to speed up the healing process, however purifying these growth factor proteins is very expensive, and they do not last long on the injured site.

Now, scientists at the Hebrew University and Harvard involved in the project have used genetic engineering to produce a "robotic" growth factor protein that responds to temperature. Increasing the temperature causes dozens of these proteins to fold together into a nanoparticle that is more than 200 times smaller than a single hair.

This behavior greatly simplifies protein purification, making it very inexpensive to produce. It also enables the growth factor to be confined and to remain at the burn or wound site. The scientists refer to their discovery as robotic, since just as robots are machines that respond to their environment by carrying out a specific activity, so too this protein they have developed responds and reacts to heat.

The experimental drug, which ha been developed by the research group as a topical ointment, has been patented and thus far has been used to treat chronic wounds in diabetic mice, dramatically increasing the healing rate. The goal is to proceed to human clinical trials at some future date after future tests and refinements.


'/>"/>

Contact: Jerry Barach
jerryb@savion.huji.ac.il
972-258-82904
The Hebrew University of Jerusalem
Source:Eurekalert  

Page: 1

Related biology technology :

1. Epitomics, Inc. Announces Worldwide Availability of LRRK2 Antibodies Developed in Partnership With The Michael J. Fox Foundation
2. Neurochip technology developed by Canadian team
3. The European HEALTHGRAIN consortium developed a definition for whole grain
4. DuPont Leader: Drought-Tolerant Crops Developed Through Modern Breeding are Key to Sustainably Increasing Grain Production
5. New Program Developed in the Fight Against Feline Aids
6. New nanotech sensor developed with medical, chemistry applications
7. New lab-on-a-chip technique developed at U of T
8. NovaBay(R) Presents Data Confirming Its Aganocide(R) Compounds Are Effective In Killing Bacteria That Have Developed Multidrug-Resistance
9. QIAGENs New Product Line, QIAsafe(R) DNA Blood, has Been Co-Developed With Biomatrica and is Based on Biomatricas SampleMatrix(R) Technology
10. New Sigma Advanced Genetic Engineering Labs Offers Research Community Unique Rodent Models Developed Using Exclusive Gene-Editing Technology
11. SAFC Supply Solutions(R) Announces Raw Materials Line Developed Specifically to Meet Molecular Diagnostics Manufacturing Requirements
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug developed by Hebrew U. and others holds promise for treatment of wounds
(Date:3/23/2017)... Research and Markets has announced the ... to their offering. ... The Global Market for Bioproducts Should Reach ... a CAGR of 8.9%, This research report ... seven major product segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs and ...
(Date:3/23/2017)... PARK, Calif., March 23, 2017  BioPharmX Corporation ... products for the dermatology market, today reported financial ... 31, 2017, and will provide an update on ... the year. "We are pleased to ... year for BioPharmX," said President Anja Krammer. "We ...
(Date:3/23/2017)... , March 23, 2017 According to a ... and derivatives market is fragmented due to the presence of a large ... Proliant, Thermo Fisher , and Sigma-Aldrich, compete with each other ... companies, collectively, held more than 76% of this market in 2016.  ... As of now, ...
(Date:3/22/2017)... , March 22, 2017 Regeneron Pharmaceuticals, Inc. ... Regeneron Genetics Center (RGC), U.K. Biobank and GSK to generate ... U.K. Biobank resource. The initiative will enable researchers to gain ... medicines for a wide range of serious and life threatening ... ...
Breaking Biology Technology:
(Date:3/2/2017)... , March 2, 2017 Summary ... better understand Merck KGaA and its partnering interests and ... https://www.reportbuyer.com/product/3605601/ Description The Partnering Deals and Alliance ... partnering activity of one of the world,s leading life ... prepared upon purchase to ensure inclusion of the most ...
(Date:2/28/2017)... , February 28, 2017 News solutions ... ... Amsterdam from 14 to 16 March, Materna will ... and show how seamless travel is a real benefit for passengers. ... added biometrics to their passenger touch point solutions to take passengers ...
(Date:2/22/2017)... LONDON , Feb. 22, 2017 ... by 2021, ABI Research identifies four technologies that ... solutions to secure significant share in the changing ... payments, and passive authentication.   "Companies ... it comes to security," says Dimitrios Pavlakis ...
Breaking Biology News(10 mins):